Two-Drug attack tested for Tough-to-Treat bladder cancer
NCT ID NCT04856189
Summary
This early-phase study tested a combination of two drugs, selinexor and pembrolizumab, for patients with advanced bladder cancer who could not receive or did not respond to standard chemotherapy. The goal was to find a safe dose and see if the combination could shrink tumors. The trial was terminated early after enrolling only four participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.